Market›Health Care›Pharmaceuticals›Pharmaceuticals
MAZE THERAPEUTICS IN

MAZE

$25.81Jan 31, 2025 – Apr 24, 2026
Health CarePharmaceuticals$1.36B
MVM
-$35.0M
TD Variance
-0.184

Every news event mapped to its market reaction — 128 events, 15 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-09-11+44.6%newsSeeking AlphaMaze Therapeutics, Inc. (MAZE) Discusses MZE782 Phase 1 Healthy Volunteer Results (Transcript)
2025-09-11+44.6%newsSeeking AlphaMaze Therapeutics, Inc. (MAZE) Special Call - Slideshow
2025-09-11+44.6%newsSeeking AlphaMaze Therapeutics climbs after early-stage trial data for rare disease drug
2025-09-11+44.6%newsSeeking AlphaMaze Therapeutics rises on $150M equity offering
2025-09-11+44.6%newsStock Titan$150M Oversubscribed Funding: Biotech Maze Therapeutics Attracts Major Healthcare Investors at Premium Price - Stock Titan
2025-09-11+44.6%newsInvestor's Business DailyWhy This Biotech, Up 55%, Was Shocked By Its Own Test Results - Investor's Business Daily
2025-09-11+44.6%newsYahoo FinanceMaze Therapeutics Announces Oversubscribed $150.0 Million Private Placement - Yahoo Finance
2025-09-11+44.6%newsBenzingaMaze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Highe - Benzinga
2026-03-25-34.0%newsInvestor's Business DailyWhy Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' Data
2026-03-25-34.0%newsMarketBeatMaze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease
2026-03-25-34.0%newsSeeking AlphaMaze Therapeutics falls despite positive mid-stage trial data for lead asset
2026-03-25-34.0%earningsSeeking AlphaMaze Therapeutics GAAP EPS of -$0.65 beats by $0.07
2026-03-25-34.0%newsInvestor's Business DailyWhy Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' Data - Investor's Business Daily
2026-03-25-34.0%newsYahoo FinanceMaze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - Yahoo Finance
2026-03-25-34.0%analystFierce BiotechAfter ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets - Fierce Biotech
2026-03-25-34.0%newsStock TitanKidney disease drug cuts proteinuria 35.6% as Maze eyes pivotal study - Stock Titan
2026-03-25-34.0%analystInvesting.comMizuho reiterates Maze Therapeutics stock rating on phase 2 data - Investing.com
2026-03-25-34.0%analystInvesting.comMaze Therapeutics stock rating reiterated at Strong Buy by Raymond James - Investing.com
2026-03-25-34.0%newsInvesting.comTruist reiterates Buy on Maze Therapeutics stock after trial data - Investing.com
2026-03-25-34.0%newsThe Motley FoolMaze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% - The Motley Fool
2026-03-25-34.0%analystInvesting.comLeerink reiterates Maze Therapeutics stock rating on trial data - Investing.com
2026-03-25-34.0%analystInvesting.comMaze Therapeutics stock rating held at Buy by TD Cowen on trial data - Investing.com
2026-03-25-34.0%analystInvesting.comBTIG reiterates Maze Therapeutics stock rating on trial results - Investing.com
2026-03-25-34.0%newsSeeking AlphaMaze Therapeutics falls despite positive mid-stage trial data for lead asset - Seeking Alpha
2026-03-25-34.0%newsInvesting.comMaze Therapeutics stock soars 22% on positive trial data for MZE829 - Investing.com
2026-03-25-34.0%newsInvesting.com South AfricaMaze Therapeutics stock soars 22% on positive trial data for MZE829 By Investing.com - Investing.com South Africa
2026-03-25-34.0%newsBioPharma DiveMaze tumbles despite positive data for kidney disease drug - BioPharma Dive
2026-03-25-34.0%newsYahoo FinanceMaze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% - Yahoo Finance
2026-03-25-34.0%analystInvesting.com South AfricaBTIG reiterates Maze Therapeutics stock rating on trial results By Investing.com - Investing.com South Africa
2026-03-25-34.0%newsTipRanksMaze Therapeutics adds Neil Kumar to board leadership - TipRanks
2026-03-25-34.0%earningsmarketscreener.comEarnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
2026-03-25-34.0%newsBenzinga12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
2025-03-31-14.3%earningsSeeking AlphaMaze Therapeutics GAAP EPS of -$18.32
2026-01-16+13.5%newsSeeking AlphaMaze Therapeutics: An Innovative, Nature-Driven Platform
2026-01-16+13.5%newsSeeking AlphaMaze Therapeutics: An Innovative, Nature-Driven Platform (NASDAQ:MAZE) - Seeking Alpha
2026-01-16+13.5%newsDirectorsTalk InterviewsMaze Therapeutics, Inc. (MAZE) Stock Analysis: A Look At Its 18.90% Potential Upside - DirectorsTalk Interviews
2026-03-10+12.2%newsInvesting.comMaze Therapeutics stock hits all-time high at 49.28 USD - Investing.com
2026-03-10+12.2%newsTipRanksWhy Maze Therapeutics Stock Is Suddenly Surging - TipRanks
2026-04-20-7.7%newsCổng thông tin điện tử Tỉnh Sơn LaIs Maze Therapeutics (MAZE) stock holding its gains (-0.96%) 2026-04-20 - High Attention Stocks - Cổng thông tin điện tử Tỉnh Sơn La
2026-04-20-7.7%newsUBND thành phố Hải PhòngIs Maze Therapeutics (MAZE) stock holding its gains (-0.96%) 2026-04-20 - High Volume Stocks - UBND thành phố Hải Phòng
2026-04-20-7.7%newsCổng thông tin điện tử tỉnh Lào CaiIs Maze Therapeutics (MAZE) stock holding its gains (-0.96%) 2026-04-20 - High Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
2025-11-11+6.5%legalSeeking AlphaMaze Therapeutics, Inc. (MAZE) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
2025-11-11+6.5%newsYahoo FinanceEvaluating Maze Therapeutics (MAZE): Is the Current Valuation Justified After Recent Volatility? - Yahoo Finance
2026-03-27-6.5%newsZacksAfter Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
2026-03-27-6.5%newsSeeking AlphaMaze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
2026-03-27-6.5%newsSeeking AlphaMaze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE) - Seeking Alpha
2026-03-27-6.5%newsYahoo FinanceAfter Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - Yahoo Finance
2026-03-27-6.5%newsqz.comAfter Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - qz.com
2026-03-27-6.5%newsZacks Investment ResearchShould I buy Maze Therapeutics, Inc. (MAZE) - Zacks Investment Research
2026-03-27-6.5%earningsZacks Investment ResearchWhat date does Maze Therapeutics, Inc.'s (MAZE) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
2025-02-15+6.3%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-02-01+6.3%newsYahoo FinanceMaze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - Yahoo Finance
2025-11-14+6.3%newsSeeking AlphaMaze Therapeutics, Inc. (MAZE) Presents at TD Cowen Immunology and Inflammation Summit Transcript
2026-04-07-5.7%newsYahoo FinanceHere is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks - Yahoo Finance
2026-04-09-5.5%newssimplywall.stAssessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks - simplywall.st
2025-09-02+5.0%executiveSeeking AlphaMaze Therapeutics names new finance chief
2026-04-08-4.7%newsInsider MonkeyHere is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks
2026-04-08-4.7%newsUBND thành phố Hải PhòngAre insiders buying or selling Maze Therapeutics (MAZE) Stock | Price at $28.23, Down 0.35% - Community Buy Alerts - UBND thành phố Hải Phòng
2026-04-01-4.7%newsInvesting.comAtul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock - Investing.com
2025-11-06-4.5%newsGlobeNewswireMaze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - GlobeNewswire
2026-03-30-4.3%newsStock TitanProposed 30,000-share option exercise by MAZE (NASDAQ: MAZE) reported - Stock Titan
2025-12-15+4.3%newssimplywall.stWe're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn - simplywall.st
2025-07-23-3.8%analystInvesting.com South AfricaH.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
2026-01-04-3.5%analysteToroMAZE Stock Price | Analyst Target 61.89 & Consensus - eToro
2026-03-11+3.2%newsAD HOC NEWSMizuho Initiates Coverage on Maze Therapeutics with Bullish $97 Target - AD HOC NEWS
2026-04-23-3.0%earningsMT NewswiresWedbush Cuts Price Target on Maze Therapeutics to $48 From $58, Keeps Outperform Rating
2025-10-17+3.0%newsSeeking AlphaMaze Therapeutics files to sell 9.23M shares of common stock for holders
2025-10-06+2.8%executiveInvesting.comMaze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
2025-12-14+2.3%newsYahoo FinanceRelief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Yahoo Finance
2025-12-19+2.1%newsStartupticker.Bumpy stock market start for Mindmaze - Startupticker.
2025-11-25+2.0%newsSeeking AlphaMaze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript
2025-12-16-1.9%newsAgefi.comMindmaze makes a volatile debut on the Swiss stock exchange - Agefi.com
2026-02-15+1.9%executiveYahoo FinanceMaze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - Yahoo Finance
2026-02-14+1.9%newsYahoo FinanceMaze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
2026-04-06-1.8%newsCổng thông tin điện tử tỉnh Tây NinhWill Maze Therapeutics (MAZE) Stock Hit Record Highs | Price at $29.45, Up 2.58% - Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
2026-04-06-1.8%newsCổng thông tin điện tử Tỉnh Sơn LaWill Maze Therapeutics (MAZE) Stock Hit Record Highs | Price at $29.45, Up 2.58% - Hot Community Stocks - Cổng thông tin điện tử Tỉnh Sơn La
2026-04-06-1.8%newsXã Châu ThànhWill Maze Therapeutics (MAZE) Stock Hit Record Highs | Price at $29.45, Up 2.58% - Pro Trader Recommendations - Xã Châu Thành
2026-04-11+1.8%newsTradingViewMAZE Options Volatility — NASDAQ:MAZE - TradingView
2025-03-26-1.6%newsSeeking AlphaMaze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist
2026-03-12+1.6%newsTradingViewMaze Therapeutics Executive Sells All Common Stock Holdings - TradingView
2026-04-21-1.6%newsInsider MonkeyTruist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
2026-04-21-1.6%earningsMarketBeat239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc - MarketBeat
2026-04-21-1.6%newsYahoo FinanceTruist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact - Yahoo Finance
2026-03-13-1.6%newsYahoo FinanceAssessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
2026-01-26+1.5%newsNasdaqMaze Therapeutics Rings the Closing Bell - Nasdaq
2026-01-26+1.5%newsNasdaqMaze Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
2025-11-07+1.2%earningsSeeking AlphaMaze Therapeutics GAAP EPS of -$0.66 misses by $0.01
2025-05-15+1.0%earningsSeeking AlphaMaze Therapeutics GAAP EPS of -$1.15
2026-03-21+1.0%earningsThe Motley FoolMaze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - The Motley Fool
2026-03-21+1.0%newsIndexBoxMaze Therapeutics (MAZE) Executive Stock Sale & 2026 Company Performance - News and Statistics - IndexBox
2026-03-21+1.0%earningsbitget.comMaze Therapeutics President Offloads Entire Insider Stake Ahead of Q4 Earnings Release - bitget.com
2026-01-08-0.8%newsTipRanksMaze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
2026-04-02-0.7%earningsMarketBeatHarold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
2026-04-02-0.7%newsStock TitanMaze Therapeutics (MAZE) executive exercises options and sells 15,000 shares - Stock Titan
2026-04-02-0.7%newsCổng thông tin điện tử Tỉnh Sơn LaAre executives confident in Maze Therapeutics (MAZE) Stock | Price at $28.71, Down 1.17% - Index Investing - Cổng thông tin điện tử Tỉnh Sơn La
2026-04-22+0.6%legalMT NewswiresMaze Therapeutics Prices $150 Million Securities Offering
2026-04-22+0.6%newsGlobeNewswireMaze Therapeutics Announces $150 Million Registered Offering
2026-04-22+0.6%newsSeeking AlphaMaze Therapeutics prices $150M equity offering
2026-04-22+0.6%newsQuiver QuantitativeMaze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds - Quiver Quantitative
2026-04-22+0.6%earningsMarketBeatMaze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's Why - MarketBeat
2026-04-22+0.6%newsmykxlg.comMaze Therapeutics Announces $150 Million Registered Offering - mykxlg.com
2026-04-22+0.6%newsChartMillMaze Therapeutics Announces $150 Million Registered Offering - ChartMill
2026-04-22+0.6%newsTipRanksMaze Therapeutics prices $150 million equity offering - TipRanks
2026-04-22+0.6%earningsCổng thông tin điện tử tỉnh Tây NinhMAZE Maze Therapeutics posts narrower Q4 2025 loss than expected, shares drop 2.37 percent amid missing quarterly revenue figures. - Short Squeeze - Cổng thông tin điện tử tỉnh Tây Ninh
2026-04-22+0.6%newsTipRanksMaze Therapeutics priced offering of 5.54M shares of common stock at $23.50 - TipRanks
2026-04-22+0.6%newsUBND thành phố Hải PhòngMaze Therapeutics (MAZE) Stock: Momentum Shift Insight (Rocket Higher) 2026-04-22 - Professional Trade Ideas - UBND thành phố Hải Phòng
2026-01-28-0.5%analystInvesting.comMaze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com
2026-04-04+0.5%executiveMotley FoolMaze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
2026-04-04+0.5%executiveThe Motley FoolMaze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - The Motley Fool
2025-10-28+0.5%executiveCNBCMaze Therapeutics has jumped more than 80% in 3 months. Its CEO is bullish on what’s to come - CNBC
2025-10-28+0.5%newsCNBCSan Francisco is making a comeback. So are these stocks from the City by the Bay - CNBC
2025-10-31-0.5%newsDirectorsTalk InterviewsMaze Therapeutics, Inc. (MAZE) Stock Analysis: 13.89% Potential Upside and Promising Clinical Trials - DirectorsTalk Interviews
2025-08-12-0.4%earningsSeeking AlphaMaze Therapeutics GAAP EPS of -$0.77 misses by $0.09
2025-12-22+0.3%newsYahoo FinanceWe Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
2025-12-04+0.3%analystInvesting.comMaze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com
2025-12-04+0.3%analystInvesting.com IndiaMaze Therapeutics stock rating initiated at Overweight by Wells Fargo By Investing.com - Investing.com India
2026-03-18-0.3%newsStock TitanOne bank pegs MindMaze at CHF 1.80, while Edison values it at CHF 3.56 - Stock Titan
2026-03-18-0.3%analystBenzingaThis Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
2025-09-17-0.3%earningsMarketBeatBiotech Breakouts: 3 Stocks With Massive Upside Potential - MarketBeat
2026-03-20-0.2%newsInvesting.comMaze Therapeutics president Bernstein sells $736k in stock - Investing.com
2025-09-19+0.1%newsYahoo FinanceMaze Therapeutics, Inc. (MAZE): A Bull Case Theory - Yahoo Finance
2026-04-26—newsInsider MonkeyWhat Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy
2026-04-26—newsYahoo FinanceWhat Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy - Yahoo Finance
2026-04-26—newsHarianBasis.coMaze Therapeutics Stock Surges with 150 Percent Upside Potential - HarianBasis.co
2026-04-25—newssimplywall.stMaze Therapeutics Raises Fresh Capital As R&D Plans And Valuation Diverge - simplywall.st
2026-04-25—newsMSNMaze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
2026-04-24—newsMSNMaze Therapeutics prices $150M equity offering - MSN
2025-01-31—newsSeeking AlphaMaze Therapeutics stock hugs flat line following $140M IPO
tickerdossier.comtickerdossier.substack.com